Palisade BIO, Inc. reported results
SEC 8-KRead source ↗
Palisade BIO, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
Who’s trading
What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.
- Insiders2 buying, 2 selling10 purchases and 4 sales by directors and officers, last 12 monthsInsider trades
- Funds83 adding, 45 cuttingOf 32 active managers that changed their stake, 17 added; quarter to June 30, 2026Fund buyers and sellers
The Fundamentalytics view
Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.
Highlights
How we pick theseStrengths
Nothing in Palisade BIO, Inc.'s latest figures clears our strength thresholds.
Things to watch
- Volatile shares. Over the past year the shares showed annualised volatility of 90% and a beta of 1.2 against the S&P 500.
- Heavily shorted. 18.2% of the shares available to trade are sold short (8.8 days of average volume to cover).
Latest results
- Earnings per share
- -$0.05 against an average estimate of -$0.05: beat by 5.4%
- Share reaction
- +1.4% in the first session after the results on August 10, 2026, against -0.3% for the S&P 500
Price chart
- 1 day+10.3%
- 1 week+2.9%
- 1 month-14.2%
- This year-52.3%
- 1 year-38.2%
- 5 years-99.9%
- S&P 500 this year+11.2%
Loading chart…
Third-party market data · may be delayed
At a glance
Earnings
- Last results
- August 10, 2026
News & updates
Company announcements, filed results and changes that matter to shareholders.
- Results
No model value for Palisade BIO, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.
Valuation models
We value Palisade BIO, Inc. as an operating company, with every model that fits that kind of business. Cost of equity 9.3%: the 10-year Treasury yield (4.9%) plus a beta of 0.96 times a 4.5% equity risk premium.
| Model | Value per share | In the combined value? |
|---|---|---|
| Price-to-earnings vs peers Earnings per share times peers' typical (harmonic-mean) price-to-earnings. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Residual income Book value plus the present value of returns above the cost of equity, fading over ten years. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Justified price-to-book Book value times (return on equity - growth) / (cost of equity - growth): steady-state returns. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Revenue-to-maturity model Revenue grown to maturity with the cash margin moving to the industry's; for companies not yet profitable. | — | Does not apply: revenue and margins don't support a positive value |
| Price-to-sales vs peers Sales per share times peers' typical price-to-sales; used only when earnings are negative. | — | Does not apply: no twelve-month earnings or share count in the filings yet |
| Combined value Weighted average of the models that apply: the primary model (price-to-earnings vs peers) counts double. Models more than 5x or less than 0.2x the share price, or more than 3x away from the other models' median, are left out. | — | No model applies: the filings don’t yet support a value. |
Different models fail in different ways, so where several apply we average them rather than trust one. Peer-based models compare Palisade BIO, Inc. with Biotechnology in our coverage, using third-party market data. Model values are estimates under stated assumptions, updated as new filings arrive; not price targets or investment advice. How each model works.
Moat
Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.
Forecasts and guidance
Analysts' consensus
| Fiscal year | EPS | Growth | Revenue | Growth |
|---|---|---|---|---|
| Current | −$0.22 | +25% | $437500 | 0% |
| Next | −$0.28 | −27% | — | −100% |
How the EPS forecast has moved
The consensus EPS forecast for the current fiscal year is −6.2% on 90 days ago. In the last 30 days, 2 analysts raised Palisade BIO, Inc.'s forecast and 5 cut it.
Average of analysts' published estimates (third-party data).
View chart data
| Period | Current fiscal year | Next fiscal year |
|---|---|---|
| 90 days ago | −$0.24 | −$0.29 |
| 60 days ago | −$0.23 | −$0.28 |
| 30 days ago | −$0.23 | −$0.28 |
| 7 days ago | −$0.22 | −$0.28 |
| Now | −$0.22 | −$0.28 |
Earnings against estimates
| Quarter to | Estimate | Actual | Surprise |
|---|---|---|---|
| Jun 2026 | −$0.05 | −$0.05 | +5.4% |
| Sept 2025 | −$0.27 | −$0.38 | −39.0% |
Adjusted EPS as companies report it, against the average analyst estimate.
Positioning
- Short interest
- 18.2% of tradable shares
- Days to cover
- 8.75 at average volume
- Short interest, 1 month
- +5% to October 15, 2026
- Held by institutions
- — of shares
- Held by insiders
- 4.6% of shares
- Employees
- 14 full time
Share-price performance
Market data may be delayedReturn and risk by year
| Calendar year | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 to date |
|---|---|---|---|---|---|---|
| Return | ||||||
| PALI | −75% | −92% | −89% | −81% | +42% | −52% |
| Industry peers (median) | −35% | −56% | −17% | −28% | −5% | −26% |
| S&P 500 | +29% | −18% | +26% | +25% | +18% | +11% |
| Months that ended higher | ||||||
| PALI | 33% | 17% | 33% | 25% | 50% | 36% |
| S&P 500 | 75% | 42% | 67% | 75% | 75% | 46% |
| Largest fall from a high during the year | ||||||
| PALI | −90% | −98% | −90% | −90% | −76% | −60% |
| S&P 500 | −5% | −25% | −10% | −8% | −19% | −9% |
Worst fall since November 3, 2015: 100% from November 3, 2015 to September 10, 2025. Getting back needed a 275166567% gain, and the shares have not yet recovered.
Price behaviour
- 52-week range
- $1.12 – $2.80
- From 52-week high
- −60.0%
- vs 50-day average
- −31.5%
- vs 200-day average
- −39.4%
- Volatility (1 year)
- 90%
- Beta vs S&P 500
- 1.21
Share price after results
- Next day
- 5 up, 7 down typical move ±10.3%
- After a week
- 7 up, 5 down typical move ±12.1%
- After a month
- 4 up, 8 down typical move ±15.2%
| Results released | Next day | S&P 500 next day | 5 days | 21 days |
|---|---|---|---|---|
| August 10, 2026 | +1.4% | −0.3% | +1.9% | −2.8% |
| May 12, 2026 | −3.6% | +0.4% | −6.7% | −8.2% |
| March 27, 2024 | +8.1% | +0.8% | +2.7% | +9.0% |
| March 23, 2021 | −8.4% | −1.3% | −18.8% | −22.3% |
| November 16, 2020 | 0.0% | +0.7% | +8.6% | +34.5% |
| August 14, 2020 | 0.0% | +0.3% | +4.2% | −13.9% |
| May 15, 2020 | +21.3% | +3.5% | +22.7% | +13.3% |
| April 2, 2020 | +12.9% | +0.8% | +8.1% | +12.9% |
| November 15, 2019 | −25.2% | +0.8% | −25.2% | −24.3% |
| August 14, 2019 | −16.4% | −2.7% | −9.2% | −14.5% |
| May 14, 2019 | +4.7% | +1.5% | +4.7% | −11.6% |
| March 22, 2019 | −21.5% | −2.0% | −32.3% | −15.4% |
Fundamentals
Who owns it
Funds buying and selling- Reported value
- $362M
- Institutions reporting
- 124
- Shares held vs prior quarter
- ▲ 16.0%
- Positions opened / closed
- 50 / 21
| Manager | Value | Shares | Share of 13F value | Shares QoQ |
|---|---|---|---|---|
| Soleus Capital Management, L.P. | $27.3M | 13.1M | 7.5% | New |
| B Group, Inc. | $23.9M | 11.4M | 6.6% | 0.0% |
| Ameriprise Financial Inc | $23.2M | 11.1M | 6.4% | ▼ 3.7% |
| Jupiter Topco LLC | $22.4M | 10.7M | 6.2% | — |
| Blackrock, Inc. | $21.8M | 10.4M | 6.0% | ▲ 456.2% |
| Octagon Capital Advisors LP | $21.5M | 10.3M | 5.9% | 0.0% |
| Perceptive Advisors LLC | $17.6M | 8.4M | 4.9% | ▼ 5.6% |
| RA Capital Management, L.P. | $14.9M | 7.1M | 4.1% | 0.0% |
| Franklin Resources Inc | $12.1M | 5.8M | 3.3% | 0.0% |
| Point72 Asset Management, L.P. | $11M | 5.3M | 3.0% | ▲ 1175.8% |
| Boxer Capital Management, LLC | $10M | 4.8M | 2.8% | 0.0% |
| Adage Capital Partners Gp, L.L.C. | $9.4M | 4.5M | 2.6% | 0.0% |
From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Palisade BIO, Inc.'s complete shareholder register. Values are as reported by the filers .
Insider trading activity
Full insider history and chart Insider purchases History → $296,650 10 trades by 2 insiders, last 12 months Insider sales History → $420,525 4 trades by 2 insiders · 0% under pre-set plans
Net ▼ $123,875 net selling
| Insider | Date | Trade | Shares | Price | Value |
|---|---|---|---|---|---|
| Williams Donald Allen Director | October 2, 2026 | Buy | 10,000 | $1.46 | $14,600 |
| Williams Donald Allen Director | October 1, 2026 | Buy | 10,000 | $1.42 | $14,200 |
| Baltera Robert Jr. Director | July 9, 2026 | Buy | 25,000 | $1.96 | $49,000 |
| Baltera Robert Jr. Director | July 8, 2026 | Buy | 20,000 | $1.99 | $39,800 |
| Finley John David CEO, CFO | July 7, 2026 | Sell | 146,798 | $2.07 | $303,872 |
| Jones Mitchell Lawrence Chief Medical Officer | July 7, 2026 | Sell | 51,880 | $2.05 | $106,354 |
| Baltera Robert Jr. Director | July 7, 2026 | Buy | 30,000 | $2.03 | $60,900 |
| Baltera Robert Jr. Director | July 6, 2026 | Buy | 20,000 | $2.05 | $41,000 |
| Baltera Robert Jr. Director | July 2, 2026 | Buy | 10,000 | $1.98 | $19,800 |
| Baltera Robert Jr. Director | July 1, 2026 | Buy | 20,000 | $1.98 | $39,600 |
| Finley John David CEO, CFO | February 12, 2026 | Sell | 3,896 | $1.75 | $6,818 |
| Jones Mitchell Lawrence Chief Medical Officer | February 12, 2026 | Sell | 1,989 | $1.75 | $3,481 |
From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.
Earnings dates and SEC filings
Results announcements
- August 10, 2026
- May 12, 2026
- March 27, 2024
- March 23, 2021
- November 16, 2020
- August 14, 2020
Recent SEC filings
- 8-K Current report
- 10-Q Quarterly report
- 8-K Current report
- S-3 S-3
- 8-K Current report
- 10-Q Quarterly report
- DEF 14A Proxy statement
- 8-K Current report
Data status
| Data | Last updated | Source |
|---|---|---|
| Share price | Exchange closing prices | |
| News and updates | Company releases and SEC 8-K filings | |
| Analyst estimates | Aggregated analyst estimates | |
| Valuation and scores | Our models, from the filed figures |
Palisade BIO, Inc. in brief
- What does Palisade BIO, Inc. do?
- Palisade BIO, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
- What is Palisade BIO, Inc.'s stock ticker?
- Palisade BIO, Inc. trades under the ticker PALI on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
- Who are Palisade BIO, Inc.'s largest institutional shareholders?
- By value reported in 13F filings for June 30, 2026, the largest reported holders are Soleus Capital Management, L.P., B Group, Inc. and Ameriprise Financial Inc. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
- Are insiders buying or selling Palisade BIO, Inc. stock?
- Over the last 12 months, Palisade BIO, Inc.'s directors and officers reported 10 open-market purchases and 4 sales on Form 4. The insider trading page charts every trade.
Follow research on Palisade BIO, Inc.
New research on the companies we cover arrives in the weekly email. Free, one email a week.